Copy to clipboard 
ATEC reported 2Q25 orthopedic sales of $185.5 million, up 27.5% compared to the second quarter of 2024. For the first half of 2025, the company generated $354.7 million in orthopedic sales, up 24.9% compared to the prior period.
The company continued its industry-leading growth in the second quarter and once again racked up an impressive scorecard across key metrics. Surgical revenue and revenue from established territories both grew 29%. Surgeon user base grew 21%. ATEC is the third largest player in the U.S. spine market and is on track for profitability by the end of 2025.
According to ATEC CEO Pat Miles, the company’s comprehensive approach to reducing complexity and variability is resonating with spine surgeons and the industry’s best salespeople.
“We’ve made statements in the past, like the spine market needs ATEC,” said Mr. Miles. “That is not a boastful comment. It’s intended to express just how unsettled the spine market is. Spine is highly complex; myriad variables that undermine durability. Spine revision rates are multiples of total joints. Total hip surgery in 10 years is around 5%, total knee surgery in 5 years is 3%. And then you’re getting 15% to 25% to 30% in short and long segment spine surgery.”
ATEC’s next step to further democratize spine surgery is the launch of its Valence navigated robotic system. The company is focused on creating a small footprint that is tightly integrated into its procedural workflows. ATEC also noted that its market share is considerably higher in areas where it has an EOS system placed. Valence and EOS could create the next growth surge for the company.
ATEC raised its full year guidance to $742 million in total revenue, reflecting growth of 21.3% compared to 2024.
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
| Segment | 2Q25 | 2Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| Spine | $153.0 | $117.0 | $36.0 | 30.8% |
| Orthobiologics | $15.6 | $13.1 | $2.5 | 19% |
| Enabling Technology | $17.0 | $15.5 | $1.5 | 9.7% |
| Total | $185.5 | $145.6 | $40.0 | 27.5% |
| Segment | 1H25 | 1H24 | $ Chg | % Chg |
|---|---|---|---|---|
| Spine | $290.8 | $227.8 | $62.9 | 27.6% |
| Orthobiologics | $30.0 | $24.9 | $5.1 | 20.5% |
| Enabling Technology | $34.0 | $31.4 | $2.6 | 8.4% |
| Total | $354.7 | $284.1 | $70.7 | 24.9% |
Orthopedic Sales by Geography
| Region | 2Q25 | 2Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $175.0 | $136.4 | $38.6 | 28.3% |
| OUS | $10.5 | $9.2 | $1.4 | 14.7% |
| Total | $185.5 | $145.6 | $40.0 | 27.5% |
| Region | 1H25 | 1H24 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $334.1 | $266.3 | $67.9 | 25.5% |
| OUS | $20.6 | $17.8 | $2.8 | 15.7% |
| Total | $354.7 | $284.1 | $70.7 | 24.9% |
Company Earnings
| Amt | % of Sales | |
|---|---|---|
| Sales | $185.5 | |
| Cost of Sales | $56.4 | 30.4% |
| Selling and Admin | $118.5 | 63.9% |
| R & D | $18.3 | 9.8% |
| Other | $33.5 | 18.1% |
| Net Earnings | ($41.2) | (22.2%) |
ATEC reported 2Q25 orthopedic sales of $185.5 million, up 27.5% compared to the second quarter of 2024. For the first half of 2025, the company generated $354.7 million in orthopedic sales, up 24.9% compared to the prior period.
The company continued its industry-leading growth in the second quarter and once again racked up an impressive...
ATEC reported 2Q25 orthopedic sales of $185.5 million, up 27.5% compared to the second quarter of 2024. For the first half of 2025, the company generated $354.7 million in orthopedic sales, up 24.9% compared to the prior period.
The company continued its industry-leading growth in the second quarter and once again racked up an impressive scorecard across key metrics. Surgical revenue and revenue from established territories both grew 29%. Surgeon user base grew 21%. ATEC is the third largest player in the U.S. spine market and is on track for profitability by the end of 2025.
According to ATEC CEO Pat Miles, the company’s comprehensive approach to reducing complexity and variability is resonating with spine surgeons and the industry’s best salespeople.
“We’ve made statements in the past, like the spine market needs ATEC,” said Mr. Miles. “That is not a boastful comment. It’s intended to express just how unsettled the spine market is. Spine is highly complex; myriad variables that undermine durability. Spine revision rates are multiples of total joints. Total hip surgery in 10 years is around 5%, total knee surgery in 5 years is 3%. And then you’re getting 15% to 25% to 30% in short and long segment spine surgery.”
ATEC’s next step to further democratize spine surgery is the launch of its Valence navigated robotic system. The company is focused on creating a small footprint that is tightly integrated into its procedural workflows. ATEC also noted that its market share is considerably higher in areas where it has an EOS system placed. Valence and EOS could create the next growth surge for the company.
ATEC raised its full year guidance to $742 million in total revenue, reflecting growth of 21.3% compared to 2024.
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
| Segment | 2Q25 | 2Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| Spine | $153.0 | $117.0 | $36.0 | 30.8% |
| Orthobiologics | $15.6 | $13.1 | $2.5 | 19% |
| Enabling Technology | $17.0 | $15.5 | $1.5 | 9.7% |
| Total | $185.5 | $145.6 | $40.0 | 27.5% |
| Segment | 1H25 | 1H24 | $ Chg | % Chg |
|---|---|---|---|---|
| Spine | $290.8 | $227.8 | $62.9 | 27.6% |
| Orthobiologics | $30.0 | $24.9 | $5.1 | 20.5% |
| Enabling Technology | $34.0 | $31.4 | $2.6 | 8.4% |
| Total | $354.7 | $284.1 | $70.7 | 24.9% |
Orthopedic Sales by Geography
| Region | 2Q25 | 2Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $175.0 | $136.4 | $38.6 | 28.3% |
| OUS | $10.5 | $9.2 | $1.4 | 14.7% |
| Total | $185.5 | $145.6 | $40.0 | 27.5% |
| Region | 1H25 | 1H24 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $334.1 | $266.3 | $67.9 | 25.5% |
| OUS | $20.6 | $17.8 | $2.8 | 15.7% |
| Total | $354.7 | $284.1 | $70.7 | 24.9% |
Company Earnings
| Amt | % of Sales | |
|---|---|---|
| Sales | $185.5 | |
| Cost of Sales | $56.4 | 30.4% |
| Selling and Admin | $118.5 | 63.9% |
| R & D | $18.3 | 9.8% |
| Other | $33.5 | 18.1% |
| Net Earnings | ($41.2) | (22.2%) |
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
